Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AADvac1 in Mild Alzheimer's Disease
NCT02579252Phase 2Completed
- Sponsor
- Axon Neuroscience
- Start
- Mar 2016
- Primary completion
- Jun 2019
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing AADvac1 with Placebo (2 arms). Primary endpoint: Safety (all-case treatment-emergent adverse events except local reactions) at 24 months. Started Mar 2016; status: completed.
02
Drugs
AADvac1
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02579252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579252.